Detect COVID-19 causative coronavirus, SARS-CoV-2
Multiplex RT-qPCR test with dual targets
(RdRp/ORF1ab) and RNA-based internal
control in a single-well
The COVID-19 pandemic has impacted testing laboratories globally. Increased testing demands, disruptions in supply, or fluctuations in staffing due to self-isolation practices all have an effect on laboratory efficiency.
PlexPCR® SARS-CoV-2 can help your laboratory work effectively.
§Monthly reports on sequence alignment are available on request.
Automation compatible workflow to maintain clinically relevant turnaround times. Includes license free, validated SpeeDx analysis software for automated result calling and simple, simultaneous data processing of large sample numbers.
* compatible with other liquid handlers, throughput may vary.
As SARS-CoV-2 continues to mutate, giving rise to variants potentially impacting diagnostic testing, laboratories need continued confidence in the results they are reporting. We routinely monitor the performance of our PlexPCR® SARS-CoV-2 assay against emerging variants to ensure you can continue to report patient test data with no hesitation.§
Demonstrated clinical performance – for more detail please see the PlexPCR® SARS-CoV-2 Instructions for Use.
|Clinical evaluation of PlexPCR® SARS-CoV-2 (n=142)|
|Positive Percent Agreement||93.26%
(95% CI 85.90 – 97.49%)
|Negative Percent Agreement||96.23%
(95% CI 87.02 – 99.54%)
|Overall rate of Agreement||94.37%
(95% CI 89.20 – 97.54%)
PlexPCR® SARS-CoV-2 is a dual-target, single-well, multiplex reverse transcriptase qPCR test for the detection of COVID-19 causing coronavirus (SARS-CoV-2) plus RNA internal control
Well 1: ORF1ab, RdRp, RNA internal control
Products are shipped on dry ice or ice gel packs.
Expiry dates are stated on the labels. It is recommended that freeze/thaw cycles be limited to less than 10. Store protected from light at – 20°C.
For in vitro diagnostic use. Not for sale in Australia or the USA.
Please contact your local representative if you can’t find what you are looking for.
We are committed to supporting continued scientific discovery and generation of clinically relevant data. Collaborations with key researchers and clinicians around the globe help us improve diagnostics and address urgent clinical needs.
Monitoring the Variants of SARS-CoV-2
In silico monitoring of the PlexPCR® SARS-CoV-2 assay inclusivity is performed monthly, with the aim to ensure new variants of the SARS-CoV-2 virus that emerge can be detected. Focused analysis is also performed on Variants of Concern (VOC) or variants of interest.
Check back for more relevant papers and publications coming soon.
Please contact SpeeDx for information about offering SpeeDx diagnostics in your clinic or for a list of current pathology clinics where SpeeDx testing is available.
|PlexPCR® SARS-CoV-2*||LC480 II
|PlexPCR® Colour Compensation^ Kit||LC480 II||2 reactions||90001|
*Not for sale in Australia or USA
†Validated on LightCycler 480 II, CFX96 Dx and CFX96 Touch
^Supplied upon request. Not for sale in USA. This kit is only required for initial set-up to establish calibration of PlexPCR® and ResistancePlus® kits on the LC480 instrument, see instruction for use for details.